LucasBio is devoted to constantly moving
forward to develop new biomedical drugs for incurable diseases.
2020.10
- Received venture certificate - Korea SME's and Startups Agency
2020.07
- Established Lucasbio's R&D Lab
2020.03
- Japanese Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 2018-521069)
2019.11
- Completed Phase I investigator-initiated clinical trial using bone-marow derived mesenchymal stem cells for chronic graft-versus-host disease
(CRIS registration No. KCT001894)
2019.07
- Establishment of LucasBio Co., Ltd.
2018.06
- Korean Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 10-1867942)
